Scott Antonia, M.D., Ph.D., is the Director of the Duke Cancer Institute's Center for Cancer Immunotherapy and serves as an instructor in the Duke University School of Medicine in Durham, North Carolina. Dr. Antonia was formerly the Chair of the Thoracic Oncology Department at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. Dr. Antonia originally joined the Moffitt Cancer Center in 1994 and previously served as the Associate Chair of the Sarcoma Department.
Dr. Antonia’s work focuses on translational research. Using his molecular biology and cellular background in the development of immunotherapeutic strategies for the treatment of cancer patients, he has developed strategies designed to thwart the immunosuppressive mechanisms used by tumors to evade T-cell mediated rejection. His clinical interests focus on immunotherapy and immunobiology, in particular, gene-modified tumor cell vaccine trials at both pre-clinical and clinical stages. He has designed and conducted numerous cutting-edge studies with novel immunotherapeutics and has two patents for technology he has developed. In addition, as a researcher and practitioner, Dr. Antonia has served as a Principal Investigator for several major clinical trials and has authored dozens of publications in peer-review journals.
Dr. Antonia's work and expertise in the field of immunology dates back to the beginning of his career and education. Dr. Antonia received his M.D. and his Ph.D. in Immunology from the University of Connecticut Health Center in Farmington, Connecticut. In addition, he completed an internal medicine residency at Yale University School of Medicine and pursued additional training at Yale through a medical oncology fellowship and post-doctoral fellowship in Immunobiology.